Stock Market Reviews

Read and share opinions on CMND (Clearmind Medicine Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
  Nov 13, 2025
• Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
  Nov 12, 2025
• Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
  Nov 10, 2025
• Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
  Nov 6, 2025
• Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
  Nov 5, 2025
• Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
  Oct 31, 2025
• Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
  Oct 30, 2025
• Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
  Oct 28, 2025
• Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
  Oct 27, 2025
• Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
  Oct 21, 2025
• Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
  Sep 25, 2025
• Clearmind Medicine Signs Deal to Raise Up to $10 Million Through Convertible Notes
  Sep 19, 2025
• Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
  Sep 19, 2025
• Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
  Aug 7, 2025
• SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
  Aug 7, 2025
• Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
  Aug 5, 2025
• Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
  Jul 30, 2025
• SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
  Jul 30, 2025